ClinicalTrials.gg
CompletedNCT04447417BALISTADUpdated Sep 18, 2025Results posted

Dupilumab Skin Barrier Function Study in Atopic Dermatitis

A Phase 4 interventional study of Dupilumab SAR231893 in Atopic Dermatitis, sponsored by Sanofi. Completed at 2 sites in 2 countries. Open to participants aged 12 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Enrollment
31st of 50
52 · median 75
Started
2020
with 3 others
Phase 4
24 of 50
4 open now
Registered
28th of 50
by date
Lead sponsor
10 of 50
Sanofi

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 31st largest by enrollment, is one of 4 that started in 2020, is one of 24 in phase 4, and was the 28th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

Primary Objective:

- Evaluate changes in skin barrier function with transepidermal water loss (TEWL) assessed after skin tape stripping (STS) in pre-defined lesional skin in participants with moderate to severe atopic dermatitis (AD) treated with dupilumab.

Secondary Objectives:

  • Evaluate changes in skin barrier function with TEWL assessed after STS in pre-defined lesional and non-lesional skin in participants with moderate to severe AD treated with dupilumab in reference to normal skin of healthy volunteers.
  • Evaluate time course of skin barrier function with TEWL assessed before and after STS in pre-defined lesional and non-lesional skin in participants with moderate to severe AD treated with dupilumab in reference to normal skin of healthy volunteers.
Read the detailed description

The duration for each participant was a total of approximately 24 weeks.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Participant must be between 12 to 65 years of age (inclusive), at the time of signing the .

Atopic dermatitis participants:

  • Male or female participants.
  • Participants with AD diagnosis according to Hanifin and Rajka criteria at least 1 year before screening.
  • Investigator Global Assessment score of >=3 at screening (on the 0-4 scale).
  • Participants with moderate to severe atopic dermatitis that were eligible to be treated with dupilumab according to product monograph.
  • Participants with AD must have had active lesions on the upper limbs or lower limbs, with severity for lesion erythema or edema/papulation >=2 at screening on the 0-3 scale of the individual signs score.
  • Patients must have had a non-lesional (normal looking) skin area 4 centimeters from the edge of the lesional area.
  • Were willing to refrain from applying any topical medication products on the target assessment areas (including lesional and non-lesional) throughout the study unless necessary to alleviate intolerable symptoms.
  • Were willing to refrain taking showers or soaking in a bathtub with soaps and body washes within 6 hours before TEWL assessments.
  • Were willing to apply Cetaphil or Vanicream moisturizer up to twice a day with an exception of moisturizer application on the targeted assessment areas (lesional and non-lesional areas) during the entire study from Day -7 to end of treatment.
  • Were willing and able to comply with all clinic visits and study-related procedures.

Healthy volunteers:

  • Age and gender matched to a selected AD participant. Adolescents aged 12 to 17 years matched by post puberty status, and adults aged 18 to 65 years were matched by age as close as possible within 10 years of age.
  • No current dermatologic or systemic condition that could interfere with the assessments.
  • use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Capable of understanding and giving signed informed consent/assent as were described in the protocol, which included compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. For adolescents >=12 and \<18 years of age a specific ICF must also be signed by the participant's legally authorized representative.

Exclusion criteria

Exclusion criteria:

  • Skin conditions other than AD that can confound assessments in the area of TEWL assessments in the opinion of the investigator (i.e., skin atrophy, ichthyosis, Netherton syndrome, severe photo damage).
  • Cracked, crusted, oozing, or bleeding AD lesions in the designated lesional assessment area leaving insufficient skin that was adequate for TEWL assessments.
  • to the active substance or to any of the of dupilumab.
  • Ocular disorder that in the opinion of the investigator could adversely affect the individual's risk for study participation. Examples include -but are not limited to- individuals with a history of active cases of herpes keratitis; Sjogren's syndrome, keratoconjunctivitis sicca or dry eye syndrome that required daily use of supplemental lubrication; or individuals with ocular conditions that required the use of ocular or cyclosporine.
  • Systemic AD treatment or phototherapy within 4 weeks of Baseline.
  • Topical AD treatment within 1 week of Baseline. Face and neck may be treated with topical steroids during the if approved by the investigator.
  • Severe concomitant illness(es) that, in the investigator's judgment, would adversely affect the participant's participation in the study. Examples included, but were not limited to participants with short , participants with uncontrolled diabetes ( >=9%), participants with cardiovascular conditions (eg, Class III or IV cardiac failure according to the classification), severe renal conditions (eg, participants on dialysis), hepato-biliary conditions (eg, class B or C), neurological conditions (eg, demyelinating diseases), active major diseases (eg, lupus, inflammatory bowel disease, rheumatoid arthritis, etc.), other severe endocrinological, gastrointestinal, metabolic, pulmonary, psychiatric (known suicidal intentions) or lymphatic diseases. The specific justification for participants excluded under this criterion were noted in study documents (chart notes, electronic case report forms, screening logs, etc.).
  • History of hypersensitivity reaction to tape or adhesives.
  • Treatment with an drug within 8 weeks or within 5 half-lives (if known) prior to Day 1, whichever was longer.
  • Current participation in another investigational clinical study.
  • Individuals accommodated in an institution because of regulatory or legal order; prisoners or participants who were legally institutionalized.
  • Participants were dependent on the Sponsor or Investigator (in conjunction with section 1.61 of the ICH-GCP Ordinance E6).
  • Individuals directly involved in the conduct of the study, or immediate family members of such individuals.
  • Any specific situation during study implementation/course that might rise ethics considerations.
  • Planned or anticipated major surgical procedure during the participant's participation in this study.
  • Pregnant or breast feeding women, or were planning to become pregnant or breastfeed during the participant's participation in this study.
  • Women unwilling to use adequate , if of * and sexually active. Adequate birth control was defined as agreement to consistently practice an effective and accepted method of contraception throughout the duration of the study and for 12 weeks after last dose of study drug. These included condom, spermicide, hormonal contraceptives, intrauterine device, or double barrier contraception (i.e., condom + diaphragm) or a male partner with documented vasectomy. Additional requirements for acceptable contraception might apply in certain countries, based on local regulations. Investigators in these countries were notified accordingly in a protocol clarification letter.

    *For females, menopause was defined as at least 12 consecutive months without menses; if in question, a follicle stimulating hormone level of >=25 milliunits per milliliter must be documented. Hysterectomy, bilateral oophorectomy, or bilateral tubal ligation must be documented, as applicable; if documented, women with these conditions were not required to use additional contraception.

  • Healthy volunteers with a personal history of an atopic condition.
  • Healthy volunteers with use of any topical treatment anywhere except Cetaphil or Vanicream moisturizer on non-targeted skin areas.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • No intervention
    Healthy Volunteer

    Healthy volunteers with age, gender, location of targeted skin lesion area and study site matched to a selected atopic dermatitis (AD) participants, received no treatment, but were monitored in similar way as like enrolled AD participants.

  • Experimental
    Atopic Dermatitis Patients

    Participants with moderate to severe AD and aged 18 years and older received dupilumab 600 milligrams (mg) (loading dose) subcutaneous (SC) injection on Day 1, followed by dupilumab 300 mg SC injection every 2 weeks (Q2W) through Week 14 (i.e., at Day 15, 29, 43, 57 and 85). Participants aged greater than or equal to (\>=) 12 to less than (\<) 18 years received treatment based on their body weight: \<60 kilograms (kg) and \>=60 kg - received dupilumab 400 mg and 600 mg (loading dose) SC injection on Day 1, respectively, followed by dupilumab 200 mg and 300 mg SC injection Q2W through Week 14 (i.e., at Day 15, 29, 43, 57 and 85).

    Drug: Dupilumab SAR231893

Interventions

  • Pharmaceutical form:solution for injection Route of administration: subcutaneous

    Also known as: REGN668

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Transepidermal Water Loss After 5 Skin Tape Stripping (STS) on Lesional Skin (LS) in AD Patients at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize skin barrier function (SBF). TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. Lesional skin (LS) areas for TEWL assessment and STS was identified at Baseline ('predefined skin area'). Within the predefined LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent Change from Baseline at Week 16 in TEWL after 5 STS on LS (first spot) in AD participants were reported in this outcome measure (OM). Here, overall number of participants analyzed=participants evaluable for this OM.

    Time frame: Baseline, Week 16

Secondary outcomes

  1. Percent Change From Baseline in TEWL After 20 STS on Lesional and Non-lesional Skin (Non-LS) in AD Patients at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS and non-LS areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS and non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from Baseline at Week 16 in TEWL after 20 STS on LS and non-LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Week 16

  2. Absolute Change in TEWL After 20 STS on Lesional and Non-lesional Skin in AD Patients at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS and non-LS areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS and non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from Baseline at Week 16 in TEWL after 20 STS on LS and non-LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Week 16

  3. Percent Change From Baseline in TEWL After 20 STS on Normal Skin in Healthy Volunteers at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from Baseline at Week 16 in TEWL after 20 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

    Time frame: Baseline, Week 16

  4. Absolute Change From Baseline in TEWL After 20 STS on Normal Skin in Healthy Volunteers at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from Baseline at Week 16 in TEWL after 20 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

    Time frame: Baseline, Week 16

  5. Percent Change From Baseline in TEWL After 15 STS on Lesional and Non-lesional Skin in AD Patients at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS and non-LS areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS and non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from Baseline at Week 16 in TEWL after 15 STS on LS and non-LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Week 16

  6. Absolute Change From Baseline in TEWL After 15 STS on Lesional and Non-lesional Skin in AD Patients at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS and non-LS areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS and non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from Baseline at Week 16 in TEWL after 15 STS on LS and non-LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Week 16

  7. Percent Change From Baseline in TEWL After 15 STS on Normal Skin in Healthy Volunteers at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from Baseline at Week 16 in TEWL after 15 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

    Time frame: Baseline, Week 16

  8. Absolute Change From Baseline in TEWL After 15 STS on Normal Skin in Healthy Volunteers at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from Baseline at Week 16 in TEWL after 15 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

    Time frame: Baseline, Week 16

  9. Percent Change From Baseline in TEWL After 10 STS on Lesional and Non-lesional Skin in AD Patients at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS and non-LS areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS and non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from Baseline at Week 16 in TEWL after 10 STS on LS and non-LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Week 16

  10. Absolute Change From Baseline in TEWL After 10 STS on Lesional and Non-lesional Skin in AD Patients at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS and non-LS areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS and non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from Baseline at Week 16 in TEWL after 10 STS on LS and non-LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Week 16

  11. Percent Change From Baseline in TEWL After 10 STS on Normal Skin in Healthy Volunteers at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from Baseline at Week 16 in TEWL after 10 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

    Time frame: Baseline, Week 16

  12. Absolute Change From Baseline in TEWL After 10 STS on Normal Skin in Healthy Volunteers at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from Baseline at Week 16 in TEWL after 10 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

    Time frame: Baseline, Week 16

  13. Absolute Change From Baseline in TEWL After 5 STS on Lesional Skin in AD Patients at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from Baseline at Week 16 in TEWL after 5 STS on LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Week 16

  14. Percent Change From Baseline in TEWL After 5 STS on Non-lesional Skin in AD Patients at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from Baseline at Week 16 in TEWL after 5 STS on non-LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Week 16

  15. Absolute Change From Baseline in TEWL After 5 STS on Non-lesional Skin in AD Patients at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from Baseline at Week 16 in TEWL after 5 STS on non-LS (first spot) in AD participants were reported in this OM.

    Time frame: Baseline, Week 16

  16. Percent Change From Baseline in TEWL After 5 STS on Normal Skin in Healthy Volunteers at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from Baseline at Week 16 in TEWL after 5 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

    Time frame: Baseline, Week 16

  17. Absolute Change From Baseline in TEWL After 5 STS on Normal Skin in Healthy Volunteers at Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from Baseline at Week 16 in TEWL after 5 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

    Time frame: Baseline, Week 16

  18. Percent Change From Baseline in TEWL Before STS on Lesional and Non-lesional Skin in AD Patients at Day 4, 8, 11, 15, 22, 29, 43, 57, 85 and Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. LS and non-LS areas for TEWL assessment were identified at Baseline ('predefined skin area'). Within predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL was measured prior to STS on pre-defined LS and non-LS areas at specified time points. At each visit, before STS, all three spots were assessed, and their value was averaged to derive a single value. Percent change from Baseline at specified time points in TEWL before STS on LS and non-LS in AD participants were reported in this OM.

    Time frame: Baseline, Day 4, 8, 11, 15, 22, 29, 43, 57, 85 and Week 16

  19. Absolute Change From Baseline up to Week 16 in TEWL Before STS on Lesional and Non-lesional Skin in AD Patients at Day 4, 8, 11, 15, 22, 29, 43, 57, 85 and Week 16

    TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. LS and non-LS areas for TEWL assessment were identified at Baseline ('predefined skin area'). Within predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL was measured prior to STS on pre-defined LS and non-LS areas at specified time points. At each visit, before STS, all three spots were assessed, and their value was averaged to derive a single value. Absolute change from Baseline at specified time points in TEWL before STS on LS and non-LS in AD participants were reported in this OM.

    Time frame: Baseline, Day 4, 8, 11, 15, 22, 29, 43, 57, 85 and Week 16

  20. Percent Change From Baseline in TEWL Before STS on Normal Skin in Healthy Volunteers at Day 4, 8, 11, 15, 22, 29, 43, 57, 85 and Week 16

    TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. Normal skin areas for TEWL assessment were identified at Baseline ('predefined skin area'). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined normal skin areas at specified time points. At each visit, before STS, all three spots were assessed, and their value was averaged to derive a single value. Percent change from Baseline at specified time points in TEWL before STS on normal skin in healthy volunteers were reported in this OM.

    Time frame: Baseline, Day 4, 8, 11, 15, 22, 29, 43, 57, 85 and Week 16

  21. Absolute Change From Baseline in TEWL Before STS on Normal Skin in Healthy Volunteers at Day 4, 8, 11, 15, 22, 29, 43, 57, 85 and Week 16

    TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. Normal skin areas for TEWL assessment were identified at Baseline ('predefined skin area'). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined normal skin areas at specified time points. At each visit, before STS, all three spots were assessed, and their value was averaged to derive a single value. Absolute change from Baseline at specified time points in TEWL before STS on normal skin in healthy volunteers were reported in this OM.

    Time frame: Baseline, Day 4, 8, 11, 15, 22, 29, 43, 57, 85 and Week 16

  22. Percent Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Lesional and Non-lesional Skin in AD Patients at Day 15, 29, 57, 85 and Week 16

    TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. LS and non-LS areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL: measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS and non-LS areas at specified time points. STS assessment was done at Baseline (Week 0, Day 1), Day 57 and Week 16 on 1st spot; at Day 15 on 2nd spot and at Day 29 and Day 85 on 3rd spot. Percent change from Baseline at specified time points in TEWL after STS on LS and non-LS in AD participants were reported in this OM.

    Time frame: Baseline, Day 15, 29, 57, 85 and Week 16

  23. Absolute Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Lesional and Non-lesional Skin in AD Patients at Day 15, 29, 57, 85 and Week 16

    TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. LS and non-LS areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL: measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS and non-LS areas at specified time points. STS assessment was done at Baseline (Week 0, Day 1), Day 57 and Week 16 on 1st spot; at Day 15 on 2nd spot and at Day 29 and Day 85 on 3rd spot. Absolute change from Baseline at specified time points in TEWL after STS on LS and non-LS in AD participants were reported in this OM.

    Time frame: Baseline, Day 15, 29, 57, 85 and Week 16

  24. Percent Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Normal Skin in Healthy Volunteers at Day 15, 29, 57, 85 and Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. Normal skin areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment was done at Baseline (Week 0, Day 1), Day 57 and Week 16 on 1st spot; at Day 15 on 2nd spot and at Day 29 and Day 85 on 3rd spot. Percent change from Baseline at specified time points in TEWL after STS on normal skin in healthy volunteers were reported in this OM.

    Time frame: Baseline, Day 15, 29, 57, 85 and Week 16

  25. Absolute Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Normal Skin in Healthy Volunteers at Day 15, 29, 57, 85 and Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. Normal skin areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment was done at Baseline (Week 0, Day 1), Day 57 and Week 16 on 1st spot; at Day 15 on 2nd spot and at Day 29 and Day 85 on 3rd spot. Absolute change from Baseline at specified time points in TEWL after STS on normal skin in healthy volunteers were reported in this OM.

    Time frame: Baseline, Day 15, 29, 57, 85 and Week 16

  26. Percent Change From Baseline in Area Under the Curve (AUC) of TEWL on Lesional and Non-lesional Skin in AD Patients at Day 15, 29, 57, 85 and Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS was used to reflect the overall integrity of the stratum corneum. LS and non-LS areas for TEWL assessment and STS was identified at Baseline ('predefined skin area'). Within the predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS and non-LS areas at specified time points. TEWL AUC was a composite measure before and after 5, 10, 15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal rule. Percent change from Baseline at specified time points in TEWL AUC in AD participants were reported in this OM.

    Time frame: Baseline, Day 15, 29, 57, 85 and Week 16

  27. Absolute Change From Baseline in Area Under the Curve of TEWL on Lesional and Non-lesional Skin in AD Patients at Day 15, 29, 57, 85 and Week 16

    TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum, used to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS was used to reflect overall integrity of the stratum corneum. LS and non-LS areas for TEWL assessment and STS was identified at Baseline ('predefined skin area'). Within predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL was measured prior to STS and after 5,10,15 and 20 STS on pre-defined LS and non-LS areas at specified time points. TEWL AUC was a composite measure before and after 5, 10, 15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal rule. Absolute change from Baseline at specified time points in TEWL AUC in AD participants were reported in this OM. Expanded unit of measure is number of skin tape stripping\*grams per square meter per hour.

    Time frame: Baseline, Day 15, 29, 57, 85 and Week 16

  28. Percent Change From Baseline in Area Under the Curve of TEWL on Normal Skin in Healthy Volunteers at Day 15, 29, 57, 85 and Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS was used to reflect the overall integrity of the stratum corneum. Normal skin areas for TEWL assessment and STS was identified at Baseline ('predefined skin area'). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL measured prior to STS and after 5,10,15 and 20 STS on pre-defined normal skin areas at specified time points. TEWL AUC was a composite measure before and after 5, 10, 15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal rule. Percent Change from Baseline at specified time points in TEWL AUC in healthy volunteers were reported in this OM.

    Time frame: Baseline, Day 15, 29, 57, 85 and Week 16

  29. Absolute Change From Baseline in TEWL Area Under the Curve (AUC) on Normal Skin in Healthy Volunteers at Day 15, 29, 57, 85 and Week 16

    TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS was used to reflect the overall integrity of the stratum corneum. Normal skin areas for TEWL assessment and STS was identified at Baseline ('predefined skin area'). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL measured prior to STS and after 5,10,15 and 20 STS on pre-defined normal skin areas at specified time points. TEWL AUC was a composite measure before and after 5, 10, 15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal rule. Absolute change from Baseline at specified time points in TEWL AUC in healthy volunteers were reported in this OM. Expanded unit of measure is number of skin tape stripping\*grams per square meter per hour.

    Time frame: Baseline, Day 15, 29, 57, 85 and Week 16

07

Results

Posted Jul 22, 2022

Participant flow

Study was conducted at 2 centers in the United States and Canada. A total of 52 eligible participants were enrolled between 16 July 2020 and 19 January 2021 under the AD participants cohort or the healthy volunteers cohort.

Participant flow — Overall Study
MilestoneHealthy VolunteerAtopic Dermatitis Patients
Started2626
Completed2326
Not completed30
Withdrew: Withdrawal by subject10
Withdrew: Failure to meet inclusion criteria10
Withdrew: Lost to follow-up10

Outcome measures

PrimaryPercent Change From Baseline in Transepidermal Water Loss After 5 Skin Tape Stripping (STS) on Lesional Skin (LS) in AD Patients at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize skin barrier function (SBF). TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. Lesional skin (LS) areas for TEWL assessment and STS was identified at Baseline ('predefined skin area'). Within the predefined LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent Change from Baseline at Week 16 in TEWL after 5 STS on LS (first spot) in AD participants were reported in this outcome measure (OM). Here, overall number of participants analyzed=participants evaluable for this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in Transepidermal Water Loss After 5 Skin Tape Stripping (STS) on Lesional Skin (LS) in AD Patients at Week 16
percent changeAtopic Dermatitis Patients
Percent Change From Baseline in Transepidermal Water Loss After 5 Skin Tape Stripping (STS) on Lesional Skin (LS) in AD Patients at Week 16-54.6 ± 18.0
Statistical analysis
  • Atopic Dermatitis Patients · linear mixed model · p = <=0.0001 (One-sided p-value. Threshold for significance at 0.05 level.) · Point estimate: 0.43 · 90% CI 0.37 to 0.49Point estimate obtained was back-transformed by exponentiation
SecondaryPercent Change From Baseline in TEWL After 20 STS on Lesional and Non-lesional Skin (Non-LS) in AD Patients at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS and non-LS areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS and non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from Baseline at Week 16 in TEWL after 20 STS on LS and non-LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 20 STS on Lesional and Non-lesional Skin (Non-LS) in AD Patients at Week 16
percent changeAtopic Dermatitis Patients
Lesional skin-47.7 ± 20.1
Non-Lesional skin16.6 ± 91.5
SecondaryAbsolute Change in TEWL After 20 STS on Lesional and Non-lesional Skin in AD Patients at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS and non-LS areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS and non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from Baseline at Week 16 in TEWL after 20 STS on LS and non-LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change in TEWL After 20 STS on Lesional and Non-lesional Skin in AD Patients at Week 16
grams per square meter per hourAtopic Dermatitis Patients
Lesional skin-42.6 ± 22.1
Non-Lesional skin-2.1 ± 26.2
SecondaryPercent Change From Baseline in TEWL After 20 STS on Normal Skin in Healthy Volunteers at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from Baseline at Week 16 in TEWL after 20 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 20 STS on Normal Skin in Healthy Volunteers at Week 16
percent changeHealthy Volunteer
Percent Change From Baseline in TEWL After 20 STS on Normal Skin in Healthy Volunteers at Week 16-5.8 ± 46.0
SecondaryAbsolute Change From Baseline in TEWL After 20 STS on Normal Skin in Healthy Volunteers at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from Baseline at Week 16 in TEWL after 20 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL After 20 STS on Normal Skin in Healthy Volunteers at Week 16
grams per square meter per hourHealthy Volunteer
Absolute Change From Baseline in TEWL After 20 STS on Normal Skin in Healthy Volunteers at Week 16-8.0 ± 19.2
SecondaryPercent Change From Baseline in TEWL After 15 STS on Lesional and Non-lesional Skin in AD Patients at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS and non-LS areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS and non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from Baseline at Week 16 in TEWL after 15 STS on LS and non-LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 15 STS on Lesional and Non-lesional Skin in AD Patients at Week 16
percent changeAtopic Dermatitis Patients
Lesional skin-51.2 ± 17.4
Non-Lesional skin25.1 ± 116.5
SecondaryAbsolute Change From Baseline in TEWL After 15 STS on Lesional and Non-lesional Skin in AD Patients at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS and non-LS areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS and non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from Baseline at Week 16 in TEWL after 15 STS on LS and non-LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL After 15 STS on Lesional and Non-lesional Skin in AD Patients at Week 16
grams per square meter per hourAtopic Dermatitis Patients
Lesional skin-43.1 ± 20.6
Non-Lesional skin-2.0 ± 23.5
SecondaryPercent Change From Baseline in TEWL After 15 STS on Normal Skin in Healthy Volunteers at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from Baseline at Week 16 in TEWL after 15 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 15 STS on Normal Skin in Healthy Volunteers at Week 16
percent changeHealthy Volunteer
Percent Change From Baseline in TEWL After 15 STS on Normal Skin in Healthy Volunteers at Week 16-7.2 ± 35.8
SecondaryAbsolute Change From Baseline in TEWL After 15 STS on Normal Skin in Healthy Volunteers at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from Baseline at Week 16 in TEWL after 15 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL After 15 STS on Normal Skin in Healthy Volunteers at Week 16
grams per square meter per hourHealthy Volunteer
Absolute Change From Baseline in TEWL After 15 STS on Normal Skin in Healthy Volunteers at Week 16-4.5 ± 11.1
SecondaryPercent Change From Baseline in TEWL After 10 STS on Lesional and Non-lesional Skin in AD Patients at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS and non-LS areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS and non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from Baseline at Week 16 in TEWL after 10 STS on LS and non-LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 10 STS on Lesional and Non-lesional Skin in AD Patients at Week 16
percent changeAtopic Dermatitis Patients
Lesional skin-54.9 ± 17.5
Non-Lesional skin26.2 ± 111.8
SecondaryAbsolute Change From Baseline in TEWL After 10 STS on Lesional and Non-lesional Skin in AD Patients at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS and non-LS areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS and non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from Baseline at Week 16 in TEWL after 10 STS on LS and non-LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL After 10 STS on Lesional and Non-lesional Skin in AD Patients at Week 16
grams per square meter per hourAtopic Dermatitis Patients
Lesional skin-41.2 ± 20.4
Non-Lesional skin-0.5 ± 17.9
SecondaryPercent Change From Baseline in TEWL After 10 STS on Normal Skin in Healthy Volunteers at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from Baseline at Week 16 in TEWL after 10 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 10 STS on Normal Skin in Healthy Volunteers at Week 16
percent changeHealthy Volunteer
Percent Change From Baseline in TEWL After 10 STS on Normal Skin in Healthy Volunteers at Week 16-2.0 ± 23.5
SecondaryAbsolute Change From Baseline in TEWL After 10 STS on Normal Skin in Healthy Volunteers at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from Baseline at Week 16 in TEWL after 10 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL After 10 STS on Normal Skin in Healthy Volunteers at Week 16
grams per square meter per hourHealthy Volunteer
Absolute Change From Baseline in TEWL After 10 STS on Normal Skin in Healthy Volunteers at Week 16-0.8 ± 4.0
SecondaryAbsolute Change From Baseline in TEWL After 5 STS on Lesional Skin in AD Patients at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The LS areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from Baseline at Week 16 in TEWL after 5 STS on LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL After 5 STS on Lesional Skin in AD Patients at Week 16
grams per square meter per hourAtopic Dermatitis Patients
Absolute Change From Baseline in TEWL After 5 STS on Lesional Skin in AD Patients at Week 16-35.1 ± 17.1
SecondaryPercent Change From Baseline in TEWL After 5 STS on Non-lesional Skin in AD Patients at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from Baseline at Week 16 in TEWL after 5 STS on non-LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 5 STS on Non-lesional Skin in AD Patients at Week 16
percent changeAtopic Dermatitis Patients
Percent Change From Baseline in TEWL After 5 STS on Non-lesional Skin in AD Patients at Week 1617.6 ± 82.2
SecondaryAbsolute Change From Baseline in TEWL After 5 STS on Non-lesional Skin in AD Patients at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The non-LS areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined non-LS areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from Baseline at Week 16 in TEWL after 5 STS on non-LS (first spot) in AD participants were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL After 5 STS on Non-lesional Skin in AD Patients at Week 16
grams per square meter per hourAtopic Dermatitis Patients
Absolute Change From Baseline in TEWL After 5 STS on Non-lesional Skin in AD Patients at Week 16-0.8 ± 13.6
SecondaryPercent Change From Baseline in TEWL After 5 STS on Normal Skin in Healthy Volunteers at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Percent change from Baseline at Week 16 in TEWL after 5 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 5 STS on Normal Skin in Healthy Volunteers at Week 16
percent changeHealthy Volunteer
Percent Change From Baseline in TEWL After 5 STS on Normal Skin in Healthy Volunteers at Week 161.2 ± 21.9
SecondaryAbsolute Change From Baseline in TEWL After 5 STS on Normal Skin in Healthy Volunteers at Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, the uppermost layers of the skin are peeled away using adhesive discs. The normal skin areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment at Baseline (Week 0, Day 1) and Week 16 was conducted on first spot. Absolute change from Baseline at Week 16 in TEWL after 5 STS on normal skin (first spot) in healthy volunteers were reported in this OM.

Time frame:
Baseline, Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL After 5 STS on Normal Skin in Healthy Volunteers at Week 16
grams per square meter per hourHealthy Volunteer
Absolute Change From Baseline in TEWL After 5 STS on Normal Skin in Healthy Volunteers at Week 160.0 ± 2.7
SecondaryPercent Change From Baseline in TEWL Before STS on Lesional and Non-lesional Skin in AD Patients at Day 4, 8, 11, 15, 22, 29, 43, 57, 85 and Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. LS and non-LS areas for TEWL assessment were identified at Baseline ('predefined skin area'). Within predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL was measured prior to STS on pre-defined LS and non-LS areas at specified time points. At each visit, before STS, all three spots were assessed, and their value was averaged to derive a single value. Percent change from Baseline at specified time points in TEWL before STS on LS and non-LS in AD participants were reported in this OM.

Time frame:
Baseline, Day 4, 8, 11, 15, 22, 29, 43, 57, 85 and Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL Before STS on Lesional and Non-lesional Skin in AD Patients at Day 4, 8, 11, 15, 22, 29, 43, 57, 85 and Week 16
percent changeAtopic Dermatitis Patients
Lesional skin: Day 4-0.7 ± 30.1
Lesional skin: Day 8-5.3 ± 42.1
Lesional skin: Day 11-12.9 ± 32.6
Lesional skin: Day 15-16.3 ± 34.5
Lesional skin: Day 22-37.8 ± 20.6
Lesional skin: Day 29-35.1 ± 19.9
Lesional skin: Day 43-40.6 ± 21.4
Lesional skin: Day 57-42.1 ± 20.9
Lesional skin: Day 85-42.7 ± 23.8
Lesional skin: Week 16-48.7 ± 22.6
Non-Lesional skin: Day 425.2 ± 40.6
Non-Lesional skin: Day 827.9 ± 59.5
Non-Lesional skin: Day 1120.1 ± 46.8
Non-Lesional skin: Day 1524.0 ± 56.1
Non-Lesional skin: Day 2214.5 ± 47.8
Non-Lesional skin: Day 296.4 ± 47.0
Non-Lesional skin: Day 435.6 ± 57.2
Non-Lesional skin: Day 5717.8 ± 85.4
Non-Lesional skin: Day 8527.5 ± 99.1
Non-Lesional skin: Week 1618.8 ± 85.2
SecondaryAbsolute Change From Baseline up to Week 16 in TEWL Before STS on Lesional and Non-lesional Skin in AD Patients at Day 4, 8, 11, 15, 22, 29, 43, 57, 85 and Week 16

TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. LS and non-LS areas for TEWL assessment were identified at Baseline ('predefined skin area'). Within predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL was measured prior to STS on pre-defined LS and non-LS areas at specified time points. At each visit, before STS, all three spots were assessed, and their value was averaged to derive a single value. Absolute change from Baseline at specified time points in TEWL before STS on LS and non-LS in AD participants were reported in this OM.

Time frame:
Baseline, Day 4, 8, 11, 15, 22, 29, 43, 57, 85 and Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline up to Week 16 in TEWL Before STS on Lesional and Non-lesional Skin in AD Patients at Day 4, 8, 11, 15, 22, 29, 43, 57, 85 and Week 16
grams per square meter per hourAtopic Dermatitis Patients
Lesional skin: Day 4-3.0 ± 14.0
Lesional skin: Day 8-5.6 ± 18.8
Lesional skin: Day 11-8.2 ± 16.0
Lesional skin: Day 15-10.4 ± 16.6
Lesional skin: Day 22-19.3 ± 14.0
Lesional skin: Day 29-17.7 ± 14.4
Lesional skin: Day 43-20.9 ± 14.9
Lesional skin: Day 57-20.9 ± 14.0
Lesional skin: Day 85-22.4 ± 16.7
Lesional skin: Week 16-24.3 ± 16.3
Non-Lesional skin: Day 42.7 ± 7.6
Non-Lesional skin: Day 83.8 ± 11.0
Non-Lesional skin: Day 112.1 ± 10.1
Non-Lesional skin: Day 152.6 ± 11.5
Non-Lesional skin: Day 220.4 ± 8.9
Non-Lesional skin: Day 29-1.2 ± 11.1
Non-Lesional skin: Day 43-1.7 ± 9.4
Non-Lesional skin: Day 57-0.9 ± 13.0
Non-Lesional skin: Day 851.0 ± 15.3
Non-Lesional skin: Week 16-0.7 ± 12.3
SecondaryPercent Change From Baseline in TEWL Before STS on Normal Skin in Healthy Volunteers at Day 4, 8, 11, 15, 22, 29, 43, 57, 85 and Week 16

TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. Normal skin areas for TEWL assessment were identified at Baseline ('predefined skin area'). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined normal skin areas at specified time points. At each visit, before STS, all three spots were assessed, and their value was averaged to derive a single value. Percent change from Baseline at specified time points in TEWL before STS on normal skin in healthy volunteers were reported in this OM.

Time frame:
Baseline, Day 4, 8, 11, 15, 22, 29, 43, 57, 85 and Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL Before STS on Normal Skin in Healthy Volunteers at Day 4, 8, 11, 15, 22, 29, 43, 57, 85 and Week 16
percent changeHealthy Volunteer
Day 442.6 ± 44.4
Day 820.5 ± 38.4
Day 1115.9 ± 31.0
Day 1516.6 ± 25.1
Day 2218.5 ± 32.2
Day 298.0 ± 20.2
Day 434.0 ± 26.2
Day 5720.3 ± 31.9
Day 856.0 ± 21.8
Week 164.3 ± 25.3
SecondaryAbsolute Change From Baseline in TEWL Before STS on Normal Skin in Healthy Volunteers at Day 4, 8, 11, 15, 22, 29, 43, 57, 85 and Week 16

TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. Normal skin areas for TEWL assessment were identified at Baseline ('predefined skin area'). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS on pre-defined normal skin areas at specified time points. At each visit, before STS, all three spots were assessed, and their value was averaged to derive a single value. Absolute change from Baseline at specified time points in TEWL before STS on normal skin in healthy volunteers were reported in this OM.

Time frame:
Baseline, Day 4, 8, 11, 15, 22, 29, 43, 57, 85 and Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL Before STS on Normal Skin in Healthy Volunteers at Day 4, 8, 11, 15, 22, 29, 43, 57, 85 and Week 16
grams per square meter per hourHealthy Volunteer
Day 43.9 ± 4.6
Day 81.4 ± 3.1
Day 111.2 ± 3.3
Day 151.5 ± 2.7
Day 221.4 ± 2.5
Day 290.4 ± 2.2
Day 43-0.1 ± 2.7
Day 571.6 ± 4.0
Day 850.1 ± 2.7
Week 160.4 ± 2.8
SecondaryPercent Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Lesional and Non-lesional Skin in AD Patients at Day 15, 29, 57, 85 and Week 16

TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. LS and non-LS areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL: measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS and non-LS areas at specified time points. STS assessment was done at Baseline (Week 0, Day 1), Day 57 and Week 16 on 1st spot; at Day 15 on 2nd spot and at Day 29 and Day 85 on 3rd spot. Percent change from Baseline at specified time points in TEWL after STS on LS and non-LS in AD participants were reported in this OM.

Time frame:
Baseline, Day 15, 29, 57, 85 and Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Lesional and Non-lesional Skin in AD Patients at Day 15, 29, 57, 85 and Week 16
percent changeAtopic Dermatitis Patients
Lesional skin: After 5 STS: Day 15-25.1 ± 34.0
Lesional skin: After 5 STS: Day 29-38.9 ± 23.4
Lesional skin: After 5 STS: Day 57-45.6 ± 23.5
Lesional skin: After 5 STS: Day 85-50.6 ± 26.7
Lesional skin: After 5 STS: Week 16-54.6 ± 18.0
Lesional skin: After 10 STS: Day 15-18.5 ± 30.7
Lesional skin: After 10 STS: Day 29-32.5 ± 29.1
Lesional skin: After 10 STS: Day 57-46.7 ± 22.4
Lesional skin: After 10 STS: Day 85-47.0 ± 25.6
Lesional skin: After 10 STS: Week 16-54.9 ± 17.5
Lesional skin: After 15 STS: Day 15-14.5 ± 24.8
Lesional skin: After 15 STS: Day 29-33.0 ± 17.7
Lesional skin: After 15 STS: Day 57-39.1 ± 22.3
Lesional skin: After 15 STS: Day 85-43.4 ± 24.4
Lesional skin: After 15 STS: Week 16-51.2 ± 17.4
Lesional skin: After 20 STS: Day 15-11.6 ± 27.9
Lesional skin: After 20 STS: Day 29-29.1 ± 18.8
Lesional skin: After 20 STS: Day 57-37.4 ± 22.9
Lesional skin: After 20 STS: Day 85-38.8 ± 28.2
Lesional skin: After 20 STS: Week 16-47.7 ± 20.1
Non-Lesional skin: After 5 STS: Day 1549.8 ± 100.0
Non-Lesional skin: After 5 STS: Day 298.0 ± 46.1
Non-Lesional skin: After 5 STS: Day 5722.8 ± 89.0
Non-Lesional skin: After 5 STS: Day 8533.7 ± 106.8
Non-Lesional skin: After 5 STS: Week 1617.6 ± 82.2
Non-Lesional skin: After 10 STS: Day 1555.1 ± 109.3
Non-Lesional skin: After 10 STS: Day 294.5 ± 52.9
Non-Lesional skin: After 10 STS: Day 5718.6 ± 91.0
Non-Lesional skin: After 10 STS: Day 8531.0 ± 116.3
Non-Lesional skin: After 10 STS: Week 1626.2 ± 111.8
Non-Lesional skin: After 15 STS: Day 1570.9 ± 128.3
Non-Lesional skin: After 15 STS: Day 292.4 ± 58.9
Non-Lesional skin: After 15 STS: Day 5723.5 ± 104.4
Non-Lesional skin: After 15 STS: Day 8534.7 ± 112.0
Non-Lesional skin: After 15 STS: Week 1625.1 ± 116.5
Non-Lesional skin: After 20 STS: Day 1553.1 ± 96.0
Non-Lesional skin: After 20 STS: Day 29-3.8 ± 53.2
Non-Lesional skin: After 20 STS: Day 5714.3 ± 80.7
Non-Lesional skin: After 20 STS: Day 8530.4 ± 104.9
Non-Lesional skin: After 20 STS: Week 1616.6 ± 91.5
SecondaryAbsolute Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Lesional and Non-lesional Skin in AD Patients at Day 15, 29, 57, 85 and Week 16

TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. LS and non-LS areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL: measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS and non-LS areas at specified time points. STS assessment was done at Baseline (Week 0, Day 1), Day 57 and Week 16 on 1st spot; at Day 15 on 2nd spot and at Day 29 and Day 85 on 3rd spot. Absolute change from Baseline at specified time points in TEWL after STS on LS and non-LS in AD participants were reported in this OM.

Time frame:
Baseline, Day 15, 29, 57, 85 and Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Lesional and Non-lesional Skin in AD Patients at Day 15, 29, 57, 85 and Week 16
grams per square meter per hourAtopic Dermatitis Patients
Lesional skin: After 5 STS: Day 15-19.4 ± 21.8
Lesional skin: After 5 STS: Day 29-27.1 ± 20.2
Lesional skin: After 5 STS: Day 57-29.4 ± 19.1
Lesional skin: After 5 STS: Day 85-34.8 ± 21.6
Lesional skin: After 5 STS: Week 16-35.1 ± 17.1
Lesional skin: After 10 STS: Day 15-17.7 ± 24.5
Lesional skin: After 10 STS: Day 29-28.3 ± 25.9
Lesional skin: After 10 STS: Day 57-35.6 ± 23.2
Lesional skin: After 10 STS: Day 85-36.2 ± 21.3
Lesional skin: After 10 STS: Week 16-41.2 ± 20.4
Lesional skin: After 15 STS: Day 15-13.3 ± 23.9
Lesional skin: After 15 STS: Day 29-27.0 ± 16.3
Lesional skin: After 15 STS: Day 57-31.4 ± 22.1
Lesional skin: After 15 STS: Day 85-33.7 ± 18.1
Lesional skin: After 15 STS: Week 16-43.1 ± 20.6
Lesional skin: After 20 STS: Day 15-13.6 ± 26.3
Lesional skin: After 20 STS: Day 29-25.5 ± 16.1
Lesional skin: After 20 STS: Day 57-33.3 ± 23.4
Lesional skin: After 20 STS: Day 85-32.2 ± 22.5
Lesional skin: After 20 STS: Week 16-42.6 ± 22.1
Non-Lesional skin: After 5 STS: Day 158.2 ± 22.1
Non-Lesional skin: After 5 STS: Day 29-1.0 ± 10.2
Non-Lesional skin: After 5 STS: Day 570.2 ± 14.8
Non-Lesional skin: After 5 STS: Day 853.4 ± 18.2
Non-Lesional skin: After 5 STS: Week 16-0.8 ± 13.6
Non-Lesional skin: After 10 STS: Day 1510.6 ± 29.0
Non-Lesional skin: After 10 STS: Day 29-2.6 ± 14.2
Non-Lesional skin: After 10 STS: Day 57-1.8 ± 18.2
Non-Lesional skin: After 10 STS: Day 852.4 ± 24.3
Non-Lesional skin: After 10 STS: Week 16-0.5 ± 17.9
Non-Lesional skin: After 15 STS: Day 1517.7 ± 37.6
Non-Lesional skin: After 15 STS: Day 29-4.8 ± 20.5
Non-Lesional skin: After 15 STS: Day 57-1.2 ± 25.5
Non-Lesional skin: After 15 STS: Day 853.8 ± 31.0
Non-Lesional skin: After 15 STS: Week 16-2.0 ± 23.5
Non-Lesional skin: After 20 STS: Day 1518.6 ± 37.7
Non-Lesional skin: After 20 STS: Day 29-7.5 ± 25.2
Non-Lesional skin: After 20 STS: Day 57-0.8 ± 27.7
Non-Lesional skin: After 20 STS: Day 855.5 ± 38.2
Non-Lesional skin: After 20 STS: Week 16-2.1 ± 26.2
SecondaryPercent Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Normal Skin in Healthy Volunteers at Day 15, 29, 57, 85 and Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. Normal skin areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment was done at Baseline (Week 0, Day 1), Day 57 and Week 16 on 1st spot; at Day 15 on 2nd spot and at Day 29 and Day 85 on 3rd spot. Percent change from Baseline at specified time points in TEWL after STS on normal skin in healthy volunteers were reported in this OM.

Time frame:
Baseline, Day 15, 29, 57, 85 and Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Normal Skin in Healthy Volunteers at Day 15, 29, 57, 85 and Week 16
percent changeHealthy Volunteer
After 5 STS: Day 1515.9 ± 27.8
After 5 STS: Day 295.2 ± 24.5
After 5 STS: Day 5716.0 ± 27.6
After 5 STS: Day 855.8 ± 26.3
After 5 STS: Week 161.2 ± 21.9
After 10 STS: Day 1517.6 ± 31.3
After 10 STS: Day 296.8 ± 27.8
After 10 STS: Day 5713.7 ± 25.9
After 10 STS: Day 853.1 ± 26.8
After 10 STS: Week 16-2.0 ± 23.5
After 15 STS: Day 1532.3 ± 80.8
After 15 STS: Day 291.6 ± 37.1
After 15 STS: Day 5715.3 ± 49.1
After 15 STS: Day 851.7 ± 60.2
After 15 STS: Week 16-7.2 ± 35.8
After 20 STS: Day 1544.2 ± 107.8
After 20 STS: Day 2931.1 ± 94.8
After 20 STS: Day 5722.0 ± 63.2
After 20 STS: Day 858.5 ± 89.4
After 20 STS: Week 16-5.8 ± 46.0
SecondaryAbsolute Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Normal Skin in Healthy Volunteers at Day 15, 29, 57, 85 and Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. With STS, uppermost layers of skin are peeled away using adhesive discs. Normal skin areas for TEWL assessment and STS were identified at Baseline ('predefined skin area'). Within predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined normal skin areas at specified time points. STS assessment was done at Baseline (Week 0, Day 1), Day 57 and Week 16 on 1st spot; at Day 15 on 2nd spot and at Day 29 and Day 85 on 3rd spot. Absolute change from Baseline at specified time points in TEWL after STS on normal skin in healthy volunteers were reported in this OM.

Time frame:
Baseline, Day 15, 29, 57, 85 and Week 16
Reported as:
Mean · grams per square meter per hour
Absolute Change From Baseline in TEWL After 5, 10, 15 and 20 STS on Normal Skin in Healthy Volunteers at Day 15, 29, 57, 85 and Week 16
grams per square meter per hourHealthy Volunteer
After 5 STS: Day 151.7 ± 3.8
After 5 STS: Day 290.2 ± 2.9
After 5 STS: Day 571.6 ± 4.2
After 5 STS: Day 850.1 ± 3.3
After 5 STS: Week 160.0 ± 2.7
After 10 STS: Day 152.1 ± 5.5
After 10 STS: Day 290.4 ± 4.0
After 10 STS: Day 571.5 ± 5.4
After 10 STS: Day 85-0.4 ± 4.2
After 10 STS: Week 16-0.8 ± 4.0
After 15 STS: Day 153.3 ± 15.0
After 15 STS: Day 29-1.9 ± 8.8
After 15 STS: Day 570.5 ± 12.8
After 15 STS: Day 85-3.0 ± 12.7
After 15 STS: Week 16-4.5 ± 11.1
After 20 STS: Day 155.6 ± 22.4
After 20 STS: Day 291.9 ± 20.5
After 20 STS: Day 570.0 ± 19.7
After 20 STS: Day 85-5.2 ± 23.3
After 20 STS: Week 16-8.0 ± 19.2
SecondaryPercent Change From Baseline in Area Under the Curve (AUC) of TEWL on Lesional and Non-lesional Skin in AD Patients at Day 15, 29, 57, 85 and Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS was used to reflect the overall integrity of the stratum corneum. LS and non-LS areas for TEWL assessment and STS was identified at Baseline ('predefined skin area'). Within the predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL was measured prior to STS and after 5, 10, 15 and 20 STS on pre-defined LS and non-LS areas at specified time points. TEWL AUC was a composite measure before and after 5, 10, 15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal rule. Percent change from Baseline at specified time points in TEWL AUC in AD participants were reported in this OM.

Time frame:
Baseline, Day 15, 29, 57, 85 and Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in Area Under the Curve (AUC) of TEWL on Lesional and Non-lesional Skin in AD Patients at Day 15, 29, 57, 85 and Week 16
percent changeAtopic Dermatitis Patients
Lesional skin: Day 15-17.0 ± 37.5
Lesional skin: Day 29-20.5 ± 39.3
Lesional skin: Day 57-24.3 ± 49.2
Lesional skin: Day 85-24.5 ± 56.9
Lesional skin: Week 16-29.2 ± 43.5
Non-Lesional skin: Day 1552.4 ± 99.9
Non-Lesional skin: Day 291.0 ± 48.8
Non-Lesional skin: Day 5717.7 ± 89.4
Non-Lesional skin: Day 8529.5 ± 105.6
Non-Lesional skin: Week 1619.4 ± 97.6
SecondaryAbsolute Change From Baseline in Area Under the Curve of TEWL on Lesional and Non-lesional Skin in AD Patients at Day 15, 29, 57, 85 and Week 16

TEWL assessment: noninvasive in vivo measurement of water loss across stratum corneum, used to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS was used to reflect overall integrity of the stratum corneum. LS and non-LS areas for TEWL assessment and STS was identified at Baseline ('predefined skin area'). Within predefined LS and non-LS areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment (3 spots on LS, 3 spots on non-LS). TEWL was measured prior to STS and after 5,10,15 and 20 STS on pre-defined LS and non-LS areas at specified time points. TEWL AUC was a composite measure before and after 5, 10, 15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal rule. Absolute change from Baseline at specified time points in TEWL AUC in AD participants were reported in this OM. Expanded unit of measure is number of skin tape stripping\*grams per square meter per hour.

Time frame:
Baseline, Day 15, 29, 57, 85 and Week 16
Reported as:
Mean · nsts*g/m^2/hour
Absolute Change From Baseline in Area Under the Curve of TEWL on Lesional and Non-lesional Skin in AD Patients at Day 15, 29, 57, 85 and Week 16
nsts*g/m^2/hourAtopic Dermatitis Patients
Lesional skin: Day 15-229.6 ± 400.8
Lesional skin: Day 29-278.0 ± 384.1
Lesional skin: Day 57-292.3 ± 409.2
Lesional skin: Day 85-284.8 ± 448.7
Lesional skin: Week 16-321.2 ± 464.2
Non-Lesional skin: Day 15230.9 ± 536.0
Non-Lesional skin: Day 29-66.2 ± 299.3
Non-Lesional skin: Day 57-22.4 ± 380.9
Non-Lesional skin: Day 8559.1 ± 483.9
Non-Lesional skin: Week 16-27.7 ± 348.1
SecondaryPercent Change From Baseline in Area Under the Curve of TEWL on Normal Skin in Healthy Volunteers at Day 15, 29, 57, 85 and Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS was used to reflect the overall integrity of the stratum corneum. Normal skin areas for TEWL assessment and STS was identified at Baseline ('predefined skin area'). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL measured prior to STS and after 5,10,15 and 20 STS on pre-defined normal skin areas at specified time points. TEWL AUC was a composite measure before and after 5, 10, 15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal rule. Percent Change from Baseline at specified time points in TEWL AUC in healthy volunteers were reported in this OM.

Time frame:
Baseline, Day 15, 29, 57, 85 and Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in Area Under the Curve of TEWL on Normal Skin in Healthy Volunteers at Day 15, 29, 57, 85 and Week 16
percent changeHealthy Volunteer
Day 1523.3 ± 51.2
Day 292.6 ± 39.6
Day 5714.0 ± 36.2
Day 851.0 ± 45.6
Week 16-5.5 ± 30.5
SecondaryAbsolute Change From Baseline in TEWL Area Under the Curve (AUC) on Normal Skin in Healthy Volunteers at Day 15, 29, 57, 85 and Week 16

TEWL assessment: a noninvasive in vivo measurement of water loss across stratum corneum that is used to characterize SBF. TEWL combined with STS measures SBF. TEWL AUC done over defined number of STS was used to reflect the overall integrity of the stratum corneum. Normal skin areas for TEWL assessment and STS was identified at Baseline ('predefined skin area'). Within the predefined normal skin areas, 3 closely adjacent non-overlapping spots identified for subsequent SBF assessment. TEWL measured prior to STS and after 5,10,15 and 20 STS on pre-defined normal skin areas at specified time points. TEWL AUC was a composite measure before and after 5, 10, 15 and 20 STS at each specified time point. AUC of TEWL: calculated for each visit using trapezoidal rule. Absolute change from Baseline at specified time points in TEWL AUC in healthy volunteers were reported in this OM. Expanded unit of measure is number of skin tape stripping\*grams per square meter per hour.

Time frame:
Baseline, Day 15, 29, 57, 85 and Week 16
Reported as:
Mean · nsts*g/m^2/hour
Absolute Change From Baseline in TEWL Area Under the Curve (AUC) on Normal Skin in Healthy Volunteers at Day 15, 29, 57, 85 and Week 16
nsts*g/m^2/hourHealthy Volunteer
Day 1549.6 ± 157.9
Day 29-17.7 ± 133.2
Day 5720.9 ± 145.2
Day 85-31.2 ± 148.4
Week 16-46.5 ± 125.5

Adverse events

Collected over For AD participants: from first dose (i.e., Day 1) of IMP administration up to end of treatment visit (i.e., Day 113). For healthy volunteers: from signature of consent form to end of study (i.e., from screening to Day 141).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Healthy Volunteer0/26 (0%)0/26 (0%)13/26 (50%)
Atopic Dermatitis Patients0/26 (0%)0/26 (0%)20/26 (76.9%)
Most frequent other events
Showing 10 of 36
Most frequent other events
EventHealthy VolunteerAtopic Dermatitis Patients
Injection Site ReactionGeneral disorders0/265/26
EcchymosisSkin and subcutaneous tissue disorders3/260/26
ArthralgiaMusculoskeletal and connective tissue disorders0/263/26
Limb InjuryInjury, poisoning and procedural complications2/260/26
Noninfective ConjunctivitisEye disorders0/262/26
MyalgiaMusculoskeletal and connective tissue disorders2/260/26
Food AllergyImmune system disorders0/262/26
Medical Device Site HaemorrhageGeneral disorders2/262/26
Dental Restoration FailureInjury, poisoning and procedural complications1/260/26
Foreign Body In EyeInjury, poisoning and procedural complications0/261/26

Baseline characteristics

Analysis was performed on safety population: all enrolled participants who actually received at least one dose of investigational medicinal product (IMP) or had at least one transepidermal water loss (TEWL)/skin tape stripping (STS) assessment and all healthy volunteers who had at least one TEWL/STS assessment performed.

Age, Continuous
Age, Continuous(years)Healthy VolunteerAtopic Dermatitis PatientsTotal Title
Mean33.4 ± 16.432.2 ± 17.232.8 ± 16.7
Sex: Female, Male
Sex: Female, Male(Participants)Healthy VolunteerAtopic Dermatitis PatientsTotal Title
Female111122
Male151530
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Healthy VolunteerAtopic Dermatitis PatientsTotal Title
American Indian or Alaska Native101
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American426
White212142
More than one race011
Unknown or Not Reported000
08

Study locations

2 sites
  • Investigational Site Number 8400001
    Denver, Colorado 80206, United States
  • Investigational Site Number 1240001
    Montreal, H2X 2V1, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Jun 2021, 11 months.

Results were first posted in Jul 2022, 1 year 1 month after primary completion.

Of 45 phase 4 interventional studies under Dermatitis, Atopic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2020
First posted
Jun 25, 2020
StartActual
Jul 16, 2020
Primary completionActual
Jun 17, 2021
CompletionActual
Jun 17, 2021
Results first posted
Jul 22, 2022
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04447417
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 25, 2020
Start date
Jul 16, 2020
Primary completion
Jun 17, 2021
Completion
Jun 17, 2021
Results posted
Jul 22, 2022
Last update
Sep 18, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion